Loading...
Custom Services order now ship next day

CDKN2A

CDKN2A loss has been shown to be a significant event in a number of cancer types. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. In majority of cases CDKN2A is inactivated by homozygous deletions. One of the mechanisms by which loss of CDKN2A can occur is by hypermethylation of the promoter region for the gene.
Protein class

Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins

Predicted location

Intracellular

Single cell type specificity

Cell type enhanced (Late spermatids, Pancreatic endocrine cells, Early spermatids, Respiratory ciliated cells, Basal respiratory cells, Club cells)

Immune cell specificity

Immune cell enhanced (T-reg)

Cell line specificity

Cell line enhanced (CAPAN-2, HEK93, HeLa, SK-MEL-30)

Interaction

Heterodimer with CDK4 or CDK6. Predominant p16 complexes contained CDK6. Interacts with CDK4 (both 'T-172'-phosphorylated and non-phosphorylated forms); the interaction inhibits cyclin D-CDK4 kinase activity. Interacts with ISCO2.

Molecular function

DNA-binding [Q8N726]

More Types Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

For Research Use Only. Not For Clinical Use.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare